Entera Bio Registers Resale of 134.8M Shares from $275M Private Placement
ENTX has more than doubled off its 52-week low of $0.91 on light trading volume (0.1× avg).
Summary
Entera Bio registered the resale of 134.8 million shares from its July $275M private placement, making them freely tradable. The filing reveals 173.8 million shares outstanding and identifies 50+ institutional selling shareholders.
Key Events · Financing and Capital Events · ENTX
-
Resale Registration for 134.8M Shares
The prospectus registers 134,803,910 ordinary shares for resale — 122,961,215 shares plus 11,842,695 shares underlying pre-funded warrants — all issued in the July 28, 2026 private placement.
-
Share Count Surges to 173.8M
The filing discloses 173,834,271 ordinary shares outstanding as of August 17, 2026, reflecting the massive dilution from the $275M placement at $2.04 per share.
-
50+ Institutional Sellers Identified
Selling shareholders include BVF Partners (with two board seats), TCG Crossover, Vivo Opportunity, RA Capital, Perceptive Life Sciences, Commodore Capital, and dozens of other funds.
-
No Proceeds to Company
Entera Bio will not receive any proceeds from these resales — the company only bears registration expenses. All sale proceeds go to the selling shareholders.
Analysis · ENTX · Life Sciences
This prospectus registers the resale of 134.8 million ordinary shares issued in the July 28, 2026 private placement, making them freely tradable. The filing reveals that 173.8 million shares are now outstanding — a roughly 4.5x increase from the pre-placement share count implied by the $275M raise at $2.04 per share. The selling shareholders include BVF Partners (which secured two board seats), TCG Crossover, Vivo, RA Capital, Perceptive, and dozens of other institutional investors. While the company receives no proceeds from these resales, the registration creates a significant overhang: these investors can now sell into the market at any time. The current stock price of $3.03 is approximately 49% above the $2.04 placement price, giving early investors a substantial unrealized gain and potential incentive to sell.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTX was trading at $3.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $526.7M. The 52-week trading range was $0.91 to $4.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.